ObsEva Announces Third Quarter 2019 Financial Results
– Reports Update on Three Women’s Health Product Candidates –
– Focusing on Phase 3 Programs for Linzagolix and the Phase 2
Program for OBE022 –
– Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET –
GENEVA, Switzerland and BOSTON, MA (November 7, 2019) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the third quarter ended September 30, 2019 and announced top line results of the IMPLANT 4 trial.
"Despite the unexpected results for IMPLANT 4, we remain optimistic and committed to the development of our innovative pipeline with potentially best in class product candidates for serving unmet medical needs of millions of women. In particular, we are looking forward to PRIMROSE 2 study top line results, which we expect to announce this quarter” said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva.
Pipeline Update
1. Nolasiban
IMPLANT 4 study did not meet primary endpoint: The Company has decided to discontinue the current development of nolasiban for IVF and will be exploring potential repositioning of the product.
2. Linzagolix
·Completed Patient Randomization for Two Pivotal Phase 3 trials For Women with Uterine Fibroids (PRIMROSE 1 and PRIMROSE 2): The studies include approximately 1,000 women in total with heavy menstrual bleeding (HMB) associated with uterine fibroids. The efficacy and safety of two oral doses of linzagolix are being studied, including 100mg once daily without hormonal add-back therapy (ABT) and 200mg once daily with ABT.
·Positive Phase 2b (EDELWEISS 1) Results Presented at the American Society of Reproductive Medicine (ASRM) Annual Meeting: ObsEva presented positive 52-week results of linzagolix for treating endometriosis-associated pain.
·Phase 3 trials EDELWEISS 2 (U.S.) and EDELWEISS 3 (U.S. and Europe) Currently Enrolling Patients: Each trial will enroll approximately 450 women with endometriosis-associated pain, and will include two oral doses of linzagolix, 75mg once daily without low-dose ABT and 200mg once daily with ABT.
3. OBE022 To Delay Preterm Birth
·Data Monitoring Committee Recommended Continuation of Phase 2 Study in Europe (PROLONG): In July 2019, the independent data monitoring committee (IDMC) recommended continuing the ongoing PROLONG trial with no modifications based upon the first 30 patients enrolled in Part B. Part B is the multicenter, randomized, double-blind, placebo-controlled portion of the trial that will enroll up to 120 patients with preterm labor at a gestational age of between 24 and 34 weeks.
·
Anticipated Near-Term Milestones
ObsEva expects to achieve the following clinical and regulatory milestones in 2019 - 2020:
Fourth quarter 2019
- Linzagolix: Report six-month primary endpoint data from the PRIMROSE 2 Phase 3 trial (U.S. and Europe) to treat HMB due to uterine fibroids.
- OBE022: Receive interim update in 60 patients dosed in Part B of the PROLONG Phase 2a trial in acute pre-term labor and decide next steps in development.
Second Quarter 2020
·Linzagolix: Report six-month primary endpoint data from the Phase 3 PRIMROSE 1 trial (U.S.) of linzagolix for the treatment of HMB due to uterine fibroids.
Second Half 2020
- Linzagolix:
- Read-out 12 month data for PRIMROSE 1 and PRIMROSE 2
- Conduct pre-submission meeting with the European Medicines Agency and the U.S. Food and Drug Administration for uterine fibroid indication.
- OBEO22: Report PROLONG study final results
Third Quarter 2019 Financial Results
Net loss for the third quarter of 2019 was $27.6 million, or $0.63 per share, compared with a net loss of $18.6 million, or $0.42 per share, for the third quarter of 2018. Research and development expenses were $21.9 million and general and administrative expenses were $4.9 million for the third quarter of 2019, compared with $15.9 million and $3.1 million, respectively, for the third quarter of 2018. The net loss for the third quarter of 2019 included non-cash expenses of $3.0 million for stock-based compensation, compared with $2.0 million in the prior-year period.
As of September 30, 2019, the Company had cash and cash equivalents of $91.0 million, compared with $138.6 million as of December 31, 2018.
The full Q3 2019 financial report shall be available from November 11, 2019, in the financial reports section of the Company’s website.
To access the financial reports section of the Company’s website, please click [].
To access the Q3 2019 financial report directly, please click [].
Conference Call Today
ObsEva will host a conference call and audio webcast today beginning at 8:00 a.m. Eastern Time/2:00 p.m. Central European Time to provide a business update and discuss the third quarter results. Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers and referring to conference ID 9273485. A live or archived webcast of the conference call can be accessed under the “Investors” section of ObsEva’s website .
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit .
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates, the timing of enrollment in and data from clinical trials and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2018, the Risk Factors filed as Exhibit 99.1 to ObsEva’s Form 6-K filed on August 7, 2019, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at . Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
Office
7 Mobile
Media Contact U.S.:
Marion Janic
RooneyPartners LLC
Office
Mobile
CEO Office Contact:
Shauna Dillon
Investor Contact:
Mario Corso
Senior Director, Investor Relations
Office
Mobile
Consolidated Statements of Comprehensive Loss
| Three-month period ended September 30, | Nine-Month Period Ended September 30, | |||||||||||||||
| (in USD ’000, except share and per share data) - unaudited | 2019 | 2018 | 2019 | 2018 | ||||||||||||
| Operating income other than revenue | 5 | 2 | 11 | 10 | ||||||||||||
| OPERATING EXPENSES | ||||||||||||||||
| Research and development expenses | (21,935 | ) | (15,909 | ) | (70,513 | ) | (46,945 | ) | ||||||||
| General and administrative expenses | (4,865 | ) | (3,137 | ) | (16,306 | ) | (10,287 | ) | ||||||||
| Total operating expenses | (26,800 | ) | (19,045 | ) | (86,819 | ) | (57,231 | ) | ||||||||
| OPERATING LOSS | (26,795 | ) | (19,043 | ) | (86,808 | ) | (57,221 | ) | ||||||||
| Finance income | 219 | 430 | 425 | 616 | ||||||||||||
| Finance expense | (1,021 | ) | — | (1,608 | ) | — | ||||||||||
| NET LOSS BEFORE TAX | (27,597 | ) | (18,613 | ) | (87,991 | ) | (56,605 | ) | ||||||||
| Income tax (expense) | (10 | ) | 23 | (51 | ) | 23 | ||||||||||
| NET LOSS FOR THE PERIOD | (27,607 | ) | (18,590 | ) | (88,042 | ) | (56,582 | ) | ||||||||
| Net loss per share | ||||||||||||||||
| Basic | (0.63 | ) | (0.42 | ) | (2.01 | ) | (1.45 | ) | ||||||||
| Diluted | (0.63 | ) | (0.42 | ) | (2.01 | ) | (1.45 | ) | ||||||||
| Weighted Average Number of Shares Outstanding | 43,739,938 | 43,196,686 | 43,693,245 | 39,092,256 | ||||||||||||
Consolidated Balance Sheets
| (in USD ’000) - unaudited | September 30, 2019 | December 31, 2018 | ||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | 91,017 | 138,640 | ||||||
| Other receivables | 776 | 885 | ||||||
| Prepaid expenses | 5,964 | 5,715 | ||||||
| Total current assets | 97,757 | 145,240 | ||||||
| Non-current assets | ||||||||
| Right-of-use assets | 2,202 | — | ||||||
| Furniture, fixtures and equipment | 261 | 319 | ||||||
| Intangible assets | 26,608 | 21,608 | ||||||
| Other long-term assets | 270 | 273 | ||||||
| Total non-current assets | 29,341 | 22,200 | ||||||
| Total assets | 127,098 | 167,440 | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Current tax liability | 46 | — | ||||||
| Other payables and current liabilities | 6,515 | 2,766 | ||||||
| Accrued expenses | 19,595 | 14,163 | ||||||
| Current lease liabilities | 598 | — | ||||||
| Total current liabilities | 26,754 | 16,929 | ||||||
| Non-current liabilities | ||||||||
| Non-current lease liabilities | 1,665 | — | ||||||
| Non-current borrowings | 24,830 | — | ||||||
| Post-employment obligations | 3,608 | 3,547 | ||||||
| Other long-term liabilities | 414 | 48 | ||||||
| Total non-current liabilities | 30,517 | 3,595 | ||||||
| Shareholders’ equity | ||||||||
| Share capital | 3,448 | 3,420 | ||||||
| Share premium | 318,226 | 314,565 | ||||||
| Reserves | 20,122 | 12,858 | ||||||
| Accumulated losses | (271,969 | ) | (183,927 | ) | ||||
| Total shareholders’ equity | 69,827 | 146,916 | ||||||
| Total liabilities and shareholders’ equity | 127,098 | 167,440 | ||||||
###
Attachment
